220 related articles for article (PubMed ID: 19036672)
1. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
Dartois N; Castaing N; Gandjini H; Cooper A;
J Chemother; 2008 Oct; 20 Suppl 1():28-35. PubMed ID: 19036672
[TBL] [Abstract][Full Text] [Related]
2. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Tanaseanu C; Milutinovic S; Calistru PI; Strausz J; Zolubas M; Chernyak V; Dartois N; Castaing N; Gandjini H; Cooper CA;
BMC Pulm Med; 2009 Sep; 9():44. PubMed ID: 19740418
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.
Fomin P; Beuran M; Gradauskas A; Barauskas G; Datsenko A; Dartois N; Ellis-Grosse E; Loh E;
Int J Surg; 2005; 3(1):35-47. PubMed ID: 17462257
[TBL] [Abstract][Full Text] [Related]
8. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
9. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
Teras J; Gardovskis J; Vaasna T; Kupcs U; Pupelis G; Dukart G; Dartois N; Jouve S; Cooper A;
J Chemother; 2008 Oct; 20 Suppl 1():20-7. PubMed ID: 19036671
[TBL] [Abstract][Full Text] [Related]
10. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Leroy O; Saux P; Bédos JP; Caulin E
Chest; 2005 Jul; 128(1):172-83. PubMed ID: 16002932
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
[TBL] [Abstract][Full Text] [Related]
14. Tigecycline: in community-acquired pneumonia.
McKeage K; Keating GM
Drugs; 2008; 68(18):2633-44. PubMed ID: 19093704
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors.
Dartois N; Cooper CA; Castaing N; Gandjini H; Sarkozy D
Open Respir Med J; 2013; 7():13-20. PubMed ID: 23526572
[TBL] [Abstract][Full Text] [Related]
17. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.
Ramirez JA; Cooper AC; Wiemken T; Gardiner D; Babinchak T;
BMC Infect Dis; 2012 Jul; 12():159. PubMed ID: 22812672
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin in the treatment of community-acquired pneumonia.
Noreddin AM; Elkhatib WF
Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
[TBL] [Abstract][Full Text] [Related]
20. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]